公开(公告)号：WO2020069050A3

公开(公告)日：2020-04-02

申请号：PCT/US2019/053042

申请日：2019-09-25

Applicant: ACADEMIA SINICA ,  YANG, An-Suei

Inventor： YANG, An-Suei ,  HSIEH, Shie-Liang ,  SUNG, Pei-Shan ,  HUANG, Ming-Ting ,  YU, Chung-Ming

IPC: A61K39/395 ,  A61P25/28 ,  C07K16/28

Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.

公开(公告)号：WO2020014330A1

公开(公告)日：2020-01-16

申请号：PCT/US2019/041157

申请日：2019-07-10

Applicant: ACADEMIA SINICA ,  BUDDHIST TZU CHI MEDICAL FOUNDATION ,  CHINA MEDICAL UNIVERSITY ,  SHIH, Ming-Che

Inventor： LIN, Kuo-I ,  HUNG, Shih-Chieh ,  LIU, Chin-Hsiu

IPC: C12N5/06 ,  C12N9/16

Abstract: The present invention relates to a biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis (AS). The present invention also relates to a method for producing an animal model for AS, an animal model produced therefrom, and a method for screening for an agent pharmaceutically active in the treatment of AS using such animal model.

公开(公告)号：WO2019160840A1

公开(公告)日：2019-08-22

申请号：PCT/US2019/017591

申请日：2019-02-12

Applicant: ACADEMIA SINICA ,  SHIH, Ming-Che

Inventor： JOU, Yuh-Shan ,  LANG, Yaw-Dong ,  YEH, Hsi-Wen

IPC: A61K38/01 ,  A61K38/17 ,  C07K14/435 ,  C07K14/47

Abstract: An isolated nucleic acid encoding a C-terminal fragment of paraspeckle component 1 (PSPC1) is disclosed. The C-terminal fragment of the PSPC1 comprises an extension of more than 10 but no greater than 131 amino acid residues with its C-terminal amino acid identical to the C-terminus of the PSPC1 sequence SEQ ID NO: 3 and exhibits a biological activity against tumor cells. The tumor cells are associated with either PSPC1 or protein tyrosine kinase 6 (PTK6), or both. The anti-tumor activity is at least one selected from the group consisting of: (a) suppressing tumor cell growth; (b) suppressing tumor cell progression; (c) suppressing tumor cell metastasis; (d) decreasing PSPC1 expression; and (e) decreasing oncogenic PTK6 expression in cytoplasm. Also disclosed is a peptide comprising a C-terminal fragment sequence of PSPC1. A reagent kit and method for predicting tumor progression, metastasis, and prognosis in a cancer patient are also disclosed.

公开(公告)号：WO2019094732A1

公开(公告)日：2019-05-16

申请号：PCT/US2018/060048

申请日：2018-11-09

Applicant: ACADEMIA SINICA ,  NATIONAL CHENG KUNG UNIVERSITY ,  CHEN, Ching-Shih ,  WU, Chia-Hsien ,  HSIEH, I-Shan ,  HUANG, Po-Hsien

Inventor： CHEN, Ching-Shih ,  WU, Chia-Hsien ,  HSIEH, I-Shan ,  HUANG, Po-Hsien

IPC: C07D207/34 ,  C07D213/75 ,  C07D237/20 ,  C07D241/20 ,  C07D265/12 ,  C07D291/08 ,  C07D295/104 ,  C07D471/04 ,  C07C235/56 ,  C07C309/76

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and/or the CREB-CBP pathway, ( e.g ., proliferative diseases, for example, cancer ( e.g ., lung cancer or breast cancer), and inflammatory disease ( e.g. , pancreatic fibrosis or liver fibrosis)). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

公开(公告)号：WO2018217459A3

公开(公告)日：2018-11-29

申请号：PCT/US2018/031784

申请日：2018-05-09

Applicant: ROFFLER, Steve ,  ACADEMIA SINICA

Inventor： ROFFLER, Steve ,  CHENG, Tian-lu ,  SU, Yu-Cheng ,  CHUANG, Kuo-Hsiang

IPC: C07K16/44 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00

Abstract: A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also provided is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. A kit that contains a PEG engager and a PEGylated anti-cancer agent is also disclosed. Further disclosed are methods for imaging cells and diagnosing cancer by administering a PEG engager followed by a PEGylated imaging agent. Another kit is proivided that includes the PEG engager and the PEGylated imaging agent.

公开(公告)号：WO2018130661A1

公开(公告)日：2018-07-19

申请号：PCT/EP2018/050779

申请日：2018-01-12

Applicant: ACADEMIA SINICA ,  HSIEH, Patrick C.H. ,  LUNDY, David ,  YU TAI YEN, Christopher

Inventor： HSIEH, Patrick C.H. ,  LUNDY, David ,  YU TAI YEN, Christopher

IPC: A61K47/60 ,  A61K39/395 ,  A61K9/00 ,  A61K47/36 ,  C07K16/44 ,  A61P35/00

Abstract: A drug delivery system and methods of using such for delivering a PEGylated therapeutic agent to brain. The drug delivery system may comprise an antibody, which binds polyethylene glycol (PEG), wherein the antibody is embedded in a hydrogel, which may comprise one or more biodegradable polymers, up to 60 % of which contain inter-chain or intra-chain covalent crosslinks. The amount of the antibody in the drug delivery system can be about 1-2 g per l of the hydrogel.

公开(公告)号：WO2018052964A1

公开(公告)日：2018-03-22

申请号：PCT/US2017/051310

申请日：2017-09-13

Applicant: ACADEMIA SINICA ,  SHEN, Che-Kun James ,  SHYU, Yu-Chiau ,  HUNG, Chun-Hao

Inventor： SHEN, Che-Kun James ,  SHYU, Yu-Chiau ,  HUNG, Chun-Hao

IPC: A61K38/16 ,  C07K14/47 ,  C12N5/095

Abstract: The invention found that first, the feasibility of transfer of tumor resistance and other healthy longevity characters through transplantation of bone marrow mononuclear cells (BMMNC) or hematopoietic stem cells (HSC)/hematopoietic stem and progenitor cells (HSPC) consisting of genetically engineered EKLF gene encoding the hematopoietic transcription factor EKLF. Secondly, the present invention demonstrates expression of EKLF in the long-term hematopoietic stem cells (LT-HSC), and thus EKLF as a target of regulation of hematopoiesis.

Abstract translation: 本发明首先通过移植骨髓单个核细胞（BMMNC）或造血干细胞（HSC）/造血干细胞和祖细胞（以下简称“造血干细胞”）转移肿瘤抗性和其他健康长寿特征 HSPC）由编码造血转录因子EKLF的基因工程EKLF基因组成。 其次，本发明展示了EKLF在长期造血干细胞（LT-HSC）中的表达，并且因此表明EKLF作为造血调节的靶标。

公开(公告)号：WO2018039373A1

公开(公告)日：2018-03-01

申请号：PCT/US2017/048252

申请日：2017-08-23

Applicant: CHO PHARMA INC ,  ACADEMIA SINICA ,  LIN, Nan-Horng

Inventor： LIN, Nan-Horng ,  HUANG, Lin-Ya ,  SHIVATARE, Sachin, S. ,  CHEN, Li-Tzu ,  WONG, Chi-Huey ,  WU, Chung-Yi ,  CHENG, Ting

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

Abstract translation: EndoS2的突变体在野生型EndoS2（SEQ ID NO：1）的序列中包含一个或多个突变，其中所述一个或多个突变位于位于残基133- 143，残基177-182，残基184-189，残基221-231和/或残基227-237，其中与野生型相比，EndoS2的突变体具有低水解活性和高的高糖基化活性 EndoS2。 使用EndoS2突变体制备工程化糖蛋白的方法包括将活化的寡糖偶联至糖蛋白受体。 活化的寡糖是一种聚糖恶唑啉。

公开(公告)号：WO2017165506A1

公开(公告)日：2017-09-28

申请号：PCT/US2017/023566

申请日：2017-03-22

Applicant: HU, Che-Ming, Jack ,  ACADEMIA SINICA

Inventor： HU, Che-Ming, Jack ,  CHEN, Hui-Wen ,  YAO, Bing-Yu

IPC: A61K9/51 ,  A61K48/00 ,  A61K31/522

Abstract: A polymeric nanoparticle that has a size of 30 - 600 nm in outer diameter and contains a polymeric shell, less than 25 nm in thickness and impermeable to water, one or more aqueous cores enclosed by the polymeric shell, and a bioactive agent encapsulated in each of the one or more aqueous cores. Also disclosed are a method of preparing the polymeric nanoparticle and a method of using it for treating a disease.

Abstract translation: 具有30-600nm外径尺寸并包含聚合物壳的聚合物纳米颗粒，其厚度小于25nm且不透水，一个或多个由聚合物壳包围的水性核心 和封装在一个或多个水性核心中的每一个中的生物活性剂。 还公开了制备聚合物纳米颗粒的方法和使用它治疗疾病的方法。

公开(公告)号：WO2017151625A8

公开(公告)日：2017-09-08

申请号：PCT/US2017/019964

申请日：2017-02-28

Applicant: ACADEMIA SINICA ,  WONG, Chi-Huey ,  NATIONAL TAIWAN UNIVERSITY

Inventor： WONG, Chi-Huey ,  YANG, Pan-Chyr ,  CHEIN, Rong-Jie ,  PAN, Szu-Hua ,  CHENG, Ting-Jen, R.

IPC: C07D307/92 ,  C07D333/74 ,  C07D209/56 ,  A61K31/343 ,  A61K31/381 ,  A61K31/403

Abstract: The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer ( e.g ., lung cancer), and infectious diseases ( e.g ., bacterial infections).